Apyx Medical (NASDAQ:APYX) Shares Up 3.6% - Should You Buy?

Apyx Medical Co. (NASDAQ:APYX - Get Free Report)'s stock price rose 3.6% during mid-day trading on Monday . The stock traded as high as $1.77 and last traded at $1.72. Approximately 30,375 shares traded hands during mid-day trading, a decline of 47% from the average daily volume of 57,758 shares. The stock had previously closed at $1.66.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on APYX. Craig Hallum upgraded Apyx Medical to a "strong-buy" rating in a research report on Thursday, October 24th. JMP Securities reaffirmed a "market perform" rating on shares of Apyx Medical in a research report on Monday, September 16th. Finally, BTIG Research started coverage on shares of Apyx Medical in a research report on Thursday, October 17th. They set a "neutral" rating for the company.

Apyx Medical Trading Down 0.6 %

The company has a debt-to-equity ratio of 3.03, a quick ratio of 4.52 and a current ratio of 5.46. The stock has a 50-day moving average of $1.51 and a two-hundred day moving average of $1.35. The company has a market cap of $64.37 million, a P/E ratio of -2.06 and a beta of 1.26.

Apyx Medical (NASDAQ:APYX - Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. The firm had revenue of $11.49 million during the quarter, compared to analyst estimates of $11.66 million. Apyx Medical had a negative return on equity of 137.98% and a negative net margin of 58.59%. During the same quarter in the previous year, the firm earned ($0.13) EPS. On average, equities research analysts predict that Apyx Medical Co. will post -0.68 earnings per share for the current year.

Institutional Trading of Apyx Medical

Several institutional investors have recently added to or reduced their stakes in APYX. Private Advisor Group LLC lifted its holdings in shares of Apyx Medical by 3.9% during the third quarter. Private Advisor Group LLC now owns 322,321 shares of the company's stock valued at $400,000 after purchasing an additional 12,180 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Apyx Medical by 2.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company's stock valued at $685,000 after acquiring an additional 14,481 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new stake in shares of Apyx Medical in the second quarter worth approximately $101,000. Royce & Associates LP raised its holdings in shares of Apyx Medical by 3.4% during the third quarter. Royce & Associates LP now owns 2,582,490 shares of the company's stock valued at $3,202,000 after purchasing an additional 85,267 shares during the last quarter. Finally, Rathbones Group PLC lifted its position in Apyx Medical by 148.0% during the second quarter. Rathbones Group PLC now owns 251,334 shares of the company's stock valued at $337,000 after purchasing an additional 150,000 shares during the period. 55.33% of the stock is currently owned by hedge funds and other institutional investors.

Apyx Medical Company Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.